[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473985":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":55,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":20,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":20,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental [18F]-αvβ6-BP","EXPERIMENTAL","Patients receive \\[18F\\]-αvβ6-BP BP IV and then undergo a PET\u002FCT scan over 30 minutes 60 minutes post-injection.",[13],"Drug: [18F]-αvβ6-BP",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","[18F]-αvβ6-BP","Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Julie L. Sutcliffe, PhD","The Regents of the University of California (Davis)","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Principal Investigator","CONTACT","916-734-5536","jlsutcliffe@ucdavis.edu",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":31},"Julie L Sutcliffe","9167345536",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The University of California Davis Comprehensive Cancer Center","RECRUITING","Sacramento","California","95817","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-121.4944,38.58157,{"lat":48,"lon":47},[51,52],{"name":33,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":53,"role":54,"phone":20,"phoneExt":20,"email":20},"Megan Daly, MD","SUB_INVESTIGATOR",{"type":25,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Julie L. Sutcliffe, Ph.D","Professor of Internal Medicine and Biomedical Engineering",[59],{"name":60,"class":61},"United States Department of Defense","FED","100473985","phase-1-fluorine-18-alphavbeta6-binding-peptide-positron-emission-tomography-in-metastatic-non-small-cell-lung-cancer-100473985",false,"NCT05452005","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer","Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Men and women age \\>18 yrs\n2. Biopsy proven NSCLC with brain metastases (treated or untreated)\n3. Life-expectancy of ≥3 months in the opinion of the treating physician\n4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.\n5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan\n6. Ability to understand and willingness to sign a written informed consent document.\n7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging\n8. \\[18F\\]-FDG PET\u002FCT within 21 days of enrollment\n9. MRI brain within 21 days of enrollment\n10. Eastern Cooperative Oncology Group Performance Status ≤ 2\n11. Glomerular filtration rate (GFR) ≥ 60\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Prisoners\n3. Concurrent malignancy of a different histology that could confound imaging interpretation\n4. Patients who cannot undergo PET\u002FCT scanning because of weight limits(\\>350lbs)","ALL","18 Years",{"count":72,"type":73},20,"ESTIMATED","INTERVENTIONAL",[76],"PHASE1","This study investigates fluorine-18-AlphaVBeta6-BP (\\[18F\\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \\[18F\\]-αvβ6-BP PET\u002FComputed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.",[79,80,81,82],"Lung Cancer","Lung Cancer Metastatic","Brain Metastases","Non Small Cell Lung Cancer",[84],"Positron Emission Tomography","2026-02-23",{"date":87,"type":88},"2026-02-27","ACTUAL",{"date":90,"type":88},"2022-09-13",{"date":92,"type":73},"2026-12-31",{"name":5,"class":6},1]